HOME > ARCHIVE

ARCHIVE

BUSINESS NEWS IN BRIEF -3-

July 9, 2001
CDFS Committee to Draft GL for Package Inserts for Medical Devices

July 9, 2001
BUSINESS NEWS IN BRIEF -2-

July 9, 2001
WORLD NEWS IN BRIEF

July 9, 2001
BUSINESS NEWS IN BRIEF -1-

July 9, 2001
Pharmacia Enhances R&D Organization in Japan

July 9, 2001
Shareholders' Meetings Last Longer Due to Increasing Number of Questions

July 9, 2001
Superiority of Singulaire over Pranlukast Verified: Banyu Symposium

July 9, 2001
Gap Between NHI Prices and Market Prices Widening to about 7%

July 9, 2001
Package Insert Drafting Guidebook for Medical Devices Issued

July 9, 2001
Kasamatsu Meiki, Hokuho Iyaku Tie Up in Hokuriku

July 9, 2001
Fresenius Medical Care to Become Major Player in Japan: President van Hest

July 2, 2001
Physicians Should Also Be Forbidden to Receive Gifts: Maker FTC

July 2, 2001
REGULATORY NEWS IN BRIEF

July 2, 2001
Bayer AG to Increase Share in Asia-Pacific from 16% to 25%

July 2, 2001
Japan Is Lagging Behind the US in Life Science: S&T White Paper

July 2, 2001
M&A, Alliance Effective for Strengthening R&D Ability: EAD Director

July 2, 2001
CORPORATE ROUNDUP

July 2, 2001
Aventis Aiming to Achieve Highest Growth Rate in Japan: President Loescher

July 2, 2001
Council for Regulatory Reform to Focus on Medical Fees, NHI Prices

July 2, 2001

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…